参考来源: 1. Antonia, S.J., et al., Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. N Engl J Med, 2017. 377(20): p. 1919-1929. 2. Antonia, S.J., et al., Overall Survival with Durvalumab...
我们期待Durvalumab能给局部晚期的NSCLC患者带来治愈的希望。 参考来源:1. Antonia, S.J., et al., Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. N Engl J Med, 2017. 377(20): p. 1919-1929. 2. Antonia, S.J., et al., Overall Survival with Durvalumab after Chem...
III期肺癌的患者,癌细胞还局限在单侧肺区,或者刚刚扩散至肺部的淋巴结,但还没有突破肺区扩散到骨头、大脑等其他远处器官。大部分的III期患者基本上没有手术的机会,首选治疗为同步放化疗。因此,某种程度上来说,III期不可切除的患者是在“夹缝求生”,而如何最大程度地在传统放化疗之外延长此类患者的PFS是延长III期...
Durvalumab after chemoradiotherapy in stage III non-small-cell lung can- cer. N Engl J Med 2017;377:1919-1929.Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J...
7. Paz-Ares L, Spira A, Raben D, et al: Outcomes with durvalumab by tumour PD-L1 expression in unresectable, stage III non-small-cell lung cancer in the PACIFIC trial. Ann Oncol 31:798-806, 2020 声明:本资料中...
参考文献:《Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer》 最新临床研究数据 近日,Durvalumab用于晚期NSCLC三线或以上治疗的II期临床试验ATLANTIC研究结果在《Lancet Oncology》杂志发表。 试验设计: 研究共分为3个队列: 队列1,EGFR+/ALK+ NSCLC,且PD-L1表达>=25%; ...
7. Paz-Ares L, Spira A, Raben D, et al: Outcomes with durvalumab by tumour PD-L1 expression in unresectable, stage III non-small-cell lung cancer in the PACIFIC trial. Ann Oncol 31:798-806, 2020 声明:本资料中涉及的信息仅供参考,请遵从医生或其他医疗卫生专业人士的意见或指导。
7. Paz-Ares L, Spira A, Raben D, et al: Outcomes with durvalumab by tumour PD-L1 expression in unresectable, stage III non-small-cell lung cancer in the PACIFIC trial. Ann Oncol 31:798-806, 2020 声明:本资料中涉及的信息仅供参考,请遵从医生或其他医疗卫生专业人士的意见或指导。
Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. Background:Most patients with locally advanced, unresectable, non-small-cell lung cancer (NSCLC) have disease progression despite definitive chemoradiotherapy (chemotherapy plus concurrent radiation therapy). This phase 3 study comp...
与PACIFIC研究结果相比,本研究在真实世界数据中显示了DC在不可切除的III期NSCLC患者CRT后具有良好的生存获益。血液生物标志物可以在DC治疗初始阶段预测更高级别的RP和irAEs。 SCI 19 May 2023 Korean Real-world Data on Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC) Patients Treated with Durvalumab...